Skip to main content

Table 7 Analysis of changes to haematological parameters in patients treated for arthritis

From: Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

    Number of Incidence of events (%)   
Outcome/ comparisons Celecoxib daily dose Comparator and daily dose Trials Patients Celecoxib Comparator Relative riska (95% CI) NNTpb or NNHc (95% CI)
Haemoglobin fall of 20 g/L or more       
Celecoxib v placebo Any Placebo 5 3,577 0.8 0.5 1.5 (0.56–4.0)  
Celecoxib v paracetamol Any Paracetamol 4,000 mg       
Celecoxib v rofecoxib Any Rofecoxib 25 mg       
Celecoxib (200/400) v NSAID 200–400 mg NSAID to maximum daily 10 15,746 1.1 2.2 0.71 (0.55–0.91) a 92 (66–150) b
Celecoxib (any dose) v NSAID Any NSAID to maximum daily 10 16,180 1.1 2.2 0.72 (0.56–0.92) a 93 (67–150) b
Celecoxib (any dose) v any active Any Any active comparator 11 16,990 1.1 2.1 0.72 (0.56–0.92) a 100 (71–170) b
Haematocrit fall of 5% or more       
Celecoxib v placebo Any Placebo 9 6,442 8.1 6.5 1.20 (0.98–1.5)  
Celecoxib v paracetamol Any Paracetamol 4,000 mg       
Celecoxib v rofecoxib Any Rofecoxib 25 mg 2 962 12.6 17.1 0.74 (0.54–1.01)  
Celecoxib (200/400) v NSAID 200–400 mg NSAID to maximum daily 12 6,910 9.9 15.4 0.77 (0.68–0.88) a 18 (14–25) b
Celecoxib (any dose) v NSAID Any NSAID to maximum daily 12 8,038 9.9 15.4 0.78 (0.69–0.89) a 18 (14–25) b
Celecoxib (any dose) v any active Any Any active comparator 14 8,970 10.1 15.6 0.78 (0.69–0.88) a 18 (14–25) b
  1. aRelative risk: bold indicates statistically significant difference. bNNTp (number-needed-to-treat to prevent one event) is indicated by bold. cNNH (number-needed-to-treat to harm one patient). CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug.